Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2011 (2011), Article ID 489708, 7 pages
Research Article

Assessment of Glucagon-Like Peptide-1 Analogue and Renin Inhibitor on the Binding and Regulation of GLP-1 Receptor in Type 1 Diabetic Rat Hearts

1Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut 11-236, Lebanon
2Department of Physics, Faculty of Arts and Sciences, American University of Beirut, Beirut 11-236, Lebanon

Received 8 December 2010; Revised 11 February 2011; Accepted 21 March 2011

Academic Editor: Giovanni Di Pasquale

Copyright © 2011 Shushan B. Artinian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. F. Braga and L. A. Leiter, “Role of renin-angiotensin system blockade in patients with diabetes mellitus,” The American Journal of Cardiology, vol. 104, no. 6, pp. 835–839, 2009. View at Google Scholar
  2. J. B. Marks and P. Raskin, “Cardiovascular risk in diabetes: a brief review,” Journal of Diabetes Complications, vol. 14, no. 2, pp. 108–115, 2000. View at Google Scholar
  3. D. Elahi, J. M. Egan, R. P. Shannon et al., “GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide,” Obesity, vol. 16, no. 7, pp. 1501–1509, 2008. View at Google Scholar
  4. D. J. Drucker, “The role of gut hormones in glucose homeostasis,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 24–32, 2007. View at Google Scholar
  5. S. E. Inzucchi and D. K. McGuire, “New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond,” Circulation, vol. 117, no. 4, pp. 574–584, 2008. View at Google Scholar
  6. F. K. Knop, T. Vilsbolll, P. V. Hojberg et al., “Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?” Diabetes, vol. 56, no. 8, pp. 1951–1959, 2007. View at Google Scholar
  7. J. Dupre, “Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans,” Regulatory Peptides, vol. 128, no. 2, pp. 149–157, 2005. View at Google Scholar
  8. S. Lee, D. Yabe, K. Nohtomi et al., “Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes,” Journal of Endocrinology, vol. 57, no. 2, pp. 119–126, 2010. View at Google Scholar
  9. A. J. Scheen, “Renin-angiotensin system inhibition prevents type 2 diabetes mellitus—part 1: a meta-analysis of randomised clinical trials,” Diabetes and Metabolism, vol. 30, no. 6, pp. 487–496, 2004. View at Google Scholar
  10. K. Allikmets, “Aliskiren-an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension,” Vascular Health and Risk Management, vol. 3, no. 6, pp. 809–815, 2007. View at Google Scholar
  11. J. W. Cheng, “Aliskiren: renin inhibitor for hypertension management,” Clinical Therapeutics, vol. 30, no. 1, pp. 31–47, 2008. View at Google Scholar
  12. E. A. Dubois and A. F. Cohen, “Aliskiren,” British Journal of Pharmacology, vol. 68, no. 5, pp. 653–654, 2009. View at Google Scholar
  13. E. Pimenta and S. Oparil, “Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors,” Therapeutics and Clinical Risk Management, vol. 5, no. 3, pp. 459–464, 2009. View at Google Scholar
  14. V. Chandramouli and J. R. Carter, “Cell membrane changes in chronically diabetic rats,” Diabetes, vol. 24, no. 3, pp. 257–262, 1975. View at Google Scholar
  15. W. A. Al Jaroudi, N. Nuwayri-Salti, J. A. Usta et al., “Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus,” Journal of Hypertension, vol. 23, no. 2, pp. 381–392, 2005. View at Google Scholar
  16. A. B. Bikhazi, A. M. Khalife, W. A. Jaroudi et al., “Endothelin-1 receptor subtypes expression and binding in a perfused rat model of myocardial infarction,” Comparative Biochemistry and Physiology—Part C: Toxicology and Pharmacology, vol. 134, no. 1, pp. 35–43, 2003. View at Google Scholar
  17. R. E. Haddad, A. R. Jurjus, M. Z. Ibrahim et al., “Binding of 125I-insulin on capillary endothelial and myofiber cell membranes in normal and streptozotocin-induced diabetic perfused rat hearts,” Comparative Biochemistry and Physiology—A Physiology, vol. 117, no. 4, pp. 523–530, 1997. View at Google Scholar
  18. K. Ban, M. H. Noyan-Ashraf, J. Hoefer et al., “Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways,” Circulation, vol. 117, no. 18, pp. 2340–2350, 2008. View at Google Scholar
  19. H. Hui, L. Farilla, P. Merkel, and R. Perfetti, “The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects,” European Journal of Endocrinology, vol. 146, no. 6, pp. 863–869, 2002. View at Google Scholar
  20. C. M. George, “Future trends in diabetes management,” Nephrology Nursing Journal, vol. 36, no. 5, pp. 477–483, 2009. View at Google Scholar
  21. Q. Zhou, J. Du, Z. Hu et al., “Evidence for adipose-muscle cross talk: opposing regulation of muscle proteolysis by adiponectin and Fatty acids,” Endocrinology, vol. 148, no. 12, pp. 5696–5705, 2007. View at Google Scholar
  22. H. Bugger and E. D. Abel, “Rodent models of diabetic cardiomyopathy,” Disease Models and Mechanisms, vol. 2, no. 9-10, pp. 454–466, 2009. View at Google Scholar
  23. S. Garg, E. Moser, M. P. Dain et al., “Clinical experience with insulin glargine in type 1 diabetes,” Diabetes Technology and Therapeutics, vol. 12, no. 11, pp. 835–846, 2010. View at Google Scholar
  24. Y. S. Kang, M. H. Lee, H. K. Song et al., “Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice,” Nephrology Dialysis Transplantation, vol. 26, no. 4, pp. 1194–1204, 2010. View at Google Scholar
  25. Y. Kirino, Y. Sato, and T. Kamimoto, “Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats,” Journal of Endocrinology, vol. 200, no. 1, pp. 53–61, 2009. View at Google Scholar
  26. R. Burcelin and EuCSGLP-1, “What is known, new and controversial about GLP-1? minutes of the 1st European GLP-1 Club Meeting, Marseille,” Diabetes and Metabolism, vol. 34, no. 6, pp. 627–630, 2008. View at Google Scholar
  27. T. Nystrom, M. K. Gutniak, Q. Zhang et al., “Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease,” American Journal of Physiology Endocrinology and Metabolism, vol. 287, no. 6, pp. E1209–E1215, 2004. View at Google Scholar
  28. Y. F. Dong, L. Liu, K. Kataoka et al., “prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes,” Diabetologia, vol. 53, no. 1, pp. 180–191, 2010. View at Google Scholar